Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Sell
42
HRMY Quote, Financials, Valuation and Earnings
Last price:
$34.80
Seasonality move
:
-8.14%
Day range:
$34.22 - $35.01
52-week range:
$28.14 - $41.61
Dividend yield:
0%
P/E ratio:
16.51x
P/S ratio:
2.96x
P/B ratio:
3.33x
Volume:
387.8K
Avg. volume:
512K
1-year change:
13.12%
Market cap:
$2B
Revenue:
$582M
EPS (TTM):
$2.11
Analysts' Opinion
-
Consensus RatingHarmony Biosciences Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $52.33, Harmony Biosciences Holdings has an estimated upside of 54.68% from its current price of $34.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.00 representing 100% downside risk from its current price of $34.83.
Fair Value
-
According to the consensus of 4 analysts, Harmony Biosciences Holdings has 54.68% upside to fair value with a price target of $52.33 per share.
HRMY vs. S&P 500
-
Over the past 5 trading days, Harmony Biosciences Holdings has overperformed the S&P 500 by 4.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Harmony Biosciences Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Harmony Biosciences Holdings has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Harmony Biosciences Holdings reported revenues of $186M.
Earnings Growth
-
Harmony Biosciences Holdings has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Harmony Biosciences Holdings reported earnings per share of $0.79.
Enterprise value:
1.8B
EV / Invested capital:
--
Price / LTM sales:
2.96x
EV / EBIT:
9.09x
EV / Revenue:
2.58x
PEG ratio (5yr expected):
--
EV / Free cash flow:
7.99x
Price / Operating cash flow:
9.18x
Enterprise value / EBITDA:
8.08x
Gross Profit (TTM):
$536.3M
Return On Assets:
14.52%
Net Income Margin (TTM):
17.98%
Return On Equity:
23.59%
Return On Invested Capital:
17.28%
Operating Margin:
33.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $400.8M | $541.9M | $681.9M | $160.3M | $186M | |
| Gross Profit | $326.3M | $436.9M | $536.3M | $128M | $143.3M | |
| Operating Income | $101.2M | $199.4M | $175.3M | $64.5M | $61.7M | |
| EBITDA | $123.6M | $227.8M | $217.7M | $65M | $72.5M | |
| Diluted EPS | $2.56 | $2.46 | $2.11 | $0.63 | $0.79 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $250.2M | $240.7M | $382.1M | $463M | $522.4M | |
| Total Assets | $320.1M | $391.1M | $643.5M | $777.8M | $928.1M | |
| Current Liabilities | $31.8M | $47.6M | $107.4M | $112.4M | $161.3M | |
| Total Liabilities | $225.5M | $239.1M | $299.6M | $296.4M | $331.3M | |
| Total Equity | $94.5M | $152M | $343.9M | $481.3M | $596.8M | |
| Total Debt | $192.9M | $192.1M | $191.7M | $197.1M | $182.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $155.3M | $169.4M | $220.9M | $63.1M | $70.5M | |
| Cash From Investing | -$94.9M | -$57.3M | -$96.4M | -$813K | $745K | |
| Cash From Financing | $11.3M | -$49.4M | -$61.8M | -$55.1M | -$1.2M | |
| Free Cash Flow | $115.1M | $169.2M | $220.2M | $63.1M | $70.5M | |
HRMY
Sector
Market Cap
$2B
$48.6M
Price % of 52-Week High
83.71%
47.39%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
13.12%
-33.25%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$34.44
200-day SMA
Buy
Level
$33.20
Bollinger Bands (100)
Sell
Level
33.32 - 37.2
Chaikin Money Flow
Sell
Level
-11.4M
20-day SMA
Buy
Level
$33.72
Relative Strength Index (RSI14)
Buy
Level
55.30
ADX Line
Buy
Level
25.92
Williams %R
Sell
Level
-18.3824
50-day SMA
Buy
Level
$34.12
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-21.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.8907)
Buy
CA Score
(Annual)
Level (1.4324)
Buy
Beneish M-Score
(Annual)
Level (-2.6985)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-1.425)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Stock Forecast FAQ
In the current month, HRMY has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HRMY average analyst price target in the past 3 months is $52.33.
-
Where Will Harmony Biosciences Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Harmony Biosciences Holdings share price will rise to $52.33 per share over the next 12 months.
-
What Do Analysts Say About Harmony Biosciences Holdings?
Analysts are divided on their view about Harmony Biosciences Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Harmony Biosciences Holdings is a Sell and believe this share price will drop from its current level to $31.00.
-
What Is Harmony Biosciences Holdings's Price Target?
The price target for Harmony Biosciences Holdings over the next 1-year time period is forecast to be $52.33 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HRMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Harmony Biosciences Holdings is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HRMY?
You can purchase shares of Harmony Biosciences Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Harmony Biosciences Holdings shares.
-
What Is The Harmony Biosciences Holdings Share Price Today?
Harmony Biosciences Holdings was last trading at $34.80 per share. This represents the most recent stock quote for Harmony Biosciences Holdings. Yesterday, Harmony Biosciences Holdings closed at $34.83 per share.
-
How To Buy Harmony Biosciences Holdings Stock Online?
In order to purchase Harmony Biosciences Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Sell
47
DRUG alert for Jan 3
Bright Minds Biosciences [DRUG] is down 4.28% over the past day.
Buy
88
BMA alert for Jan 3
Banco Macro SA [BMA] is up 0.88% over the past day.
Sell
50
AGFY alert for Jan 3
Agrify [AGFY] is down 5.86% over the past day.
